Valuation: Abion Inc.

Market Cap 6.09TCr 4.52Cr 4.02Cr 3.75Cr 3.42Cr 6.45Cr 434.77Cr 6.51Cr 45Cr 18Cr 222.26Cr 17Cr 17Cr 713.31Cr P/E 2024
-4.02x
P/E 2025 -7.21x
Enterprise Value 3.26TCr 2.42Cr 2.15Cr 2.01Cr 1.83Cr 3.45Cr 232.52Cr 3.48Cr 24Cr 9.41Cr 118.87Cr 9.08Cr 8.88Cr 381.49Cr EV / Sales 2024
282x
EV / Sales 2025 288x
Free-Float
73.67%
Yield 2024 *
-
Yield 2025 -
07/04 ABION Announces Preclinical Data Showing IFN-? Antibody Fusion Abn202 Outperforms Trop2-Targeting ADCs CI
04/25/04 Abion To Divest 5.9 Billion Won Worth Of Shares In Vivozon Inc RE
30/24/30 Nuon Co., Ltd. completed the acquisition of 4.06% stake in ABION Inc. from KPM TECH Co., Ltd.. CI
26/24/26 KPM TECH Co., Ltd. announced that it has received KRW 5.999999711 billion in funding from ABION Inc. CI
23/24/23 Nuon Co., Ltd. agreed to acquire 4.06% stake in ABION Inc. from KPM TECH Co., Ltd. for KRW 8 billion. CI
23/24/23 ABION Inc. announced that it has received KRW 8.0011152 billion in funding from TELCON RF PHARMACEUTICAL. Inc. CI
18/24/18 KPM TECH Co., Ltd. announced that it expects to receive KRW 5.999999711 billion in funding from ABION Inc. CI
05/24/05 ABION Inc. completed the acquisition of 7.56% stake in Vivozon, Inc. from TELCON RF PHARMACEUTICAL. Inc.. CI
05/24/05 ABION Inc. announced that it has received KRW 20.019993378 billion in funding from TELCON RF PHARMACEUTICAL. Inc. CI
11/24/11 ABION Inc. announced that it expects to receive KRW 20.019993378 billion in funding from TELCON RF PHARMACEUTICAL. Inc. CI
11/24/11 ABION Inc. agreed to acquire 7.56% stake in Vivozon, Inc. from TELCON RF PHARMACEUTICAL. Inc. for KRW 20.1 billion. CI
28/24/28 ABION Inc. announced that it expects to receive KRW 9.999995616 billion in funding from TELCON RF PHARMACEUTICAL. Inc. CI
28/23/28 Abion Inc. announced that it has received KRW 7.999997049 billion in funding from TELCON RF PHARMACEUTICAL. Inc., Gencurix Inc. CI
1 day-2.03%
3 months-14.86%
6 months-70.48%
Current year-78.40%
Current year 570
Extreme 570
4,335
1 year 570
Extreme 570
4,510
3 years 570
Extreme 570
7,277.78
5 years 570
Extreme 570
9,777.78
10 years 570
Extreme 570
14,694.44
Manager TitleAgeSince
Chief Executive Officer 55 01/08/2010
Director of Finance/CFO 45 28/03/2025
Chief Operating Officer 46 01/01/2026
Director TitleAgeSince
Director/Board Member 55 31/12/2014
Director/Board Member 56 25/03/2022
Director/Board Member 70 -
Date Insider Type Main position Quantity % Market Cap. Importance
08/12/25 Free 27 0.0001% -
08/12/25 Buy 115 0.0002%
08/12/25 Free 92 0.0002% -
Change 5-day change 1-year change 3-year change Capi.($)
-2.03%-.--%-76.33%-82.64% 4.52Cr
+4.16%+3.04%+49.37%+94.17% 7.42TCr
-3.11%-3.53%+21.92%+74.60% 5.74TCr
+0.89%-0.63%+4.28%+34.51% 4.76TCr
+0.36%+0.81%+352.17%+689.61% 4.43TCr
-0.96%-4.50%+26.36%+33.18% 4.25TCr
-0.20%-0.77%+3.74%+100.60% 4.07TCr
-0.54%+2.93%+9.31%+50.41% 3.1TCr
-2.68%+2.92%+29.63%+19.50% 2.85TCr
+0.05%-1.64%-7.28%-14.06% 2.43TCr
Average -0.41%-2.49%+41.32%+99.99% 3.91TCr
Weighted average by Cap. +0.12%-0.84%+58.75%+129.88%

Financials

2024 2025
Net sales 76Cr 6L 5L 5L 4L 8L 5.42Cr 8L 56.61L 21.94L 2.77Cr 21.18L 20.72L 8.9Cr 88Cr 7L 6L 5L 5L 9L 6.28Cr 9L 65.58L 25.41L 3.21Cr 24.54L 24L 10Cr
Net income -4.34TCr -3.22Cr -2.86Cr -2.67Cr -2.43Cr -4.59Cr -309.66Cr -4.63Cr -32Cr -13Cr -158.3Cr -12Cr -12Cr -508.05Cr -2.91TCr -2.16Cr -1.92Cr -1.79Cr -1.63Cr -3.08Cr -207.46Cr -3.1Cr -22Cr -8.39Cr -106.06Cr -8.1Cr -7.93Cr -340.37Cr
Net Debt 1.4TCr 1.04Cr 92.67L 86.49L 78.83L 1.49Cr 100.27Cr 1.5Cr 10Cr 4.06Cr 51Cr 3.92Cr 3.83Cr 164.5Cr -2.83TCr -2.1Cr -1.87Cr -1.74Cr -1.59Cr -3Cr -202.25Cr -3.03Cr -21Cr -8.18Cr -103.39Cr -7.9Cr -7.73Cr -331.82Cr
Logo Abion Inc.
ABION Inc. is a Korea-based company principally engaged in the research, development and sales of pharmaceuticals. Along with its subsidiaries, the Company operates its business through four segments including product segment, contract research organization (CRO) service segment, research segment and other segment. The Product segment produces and sells diagnostic reagents, research reagents, and stem cell culture medium. The CRO Service segment provides histopathology analysis, molecular genetic analysis, cellular immunoassay, and antibody detection services. The Research segment is engaged in research and development of drugs for protein therapeutics, nucleic acid therapeutics, and antibody therapeutics.
Employees
-
  1. Stock Market
  2. Stocks
  3. A203400 Stock